Item 8.01 Other Events.

On February 26, 2009, Spectrum Pharmaceuticals, Inc. (the "Company") reported, during its investor conference call, that revenue from the sales of its proprietary drug product, Fusilev®, launched in August 2008, was approximately $7.7 million for the period ended December 31, 2008. While shipments of Fusilev® for the period were approximately $10.8 million (net of estimates for promotional, price and other adjustments), based on the Company's revenue recognition policy, the Company has deferred the recognition of approximately $3.1 million of such revenue until the Company has more experience with the amount of product returns.

In addition, the Company had cash and marketable securities of approximately $78 million as of December 31, 2008.